LKFT on Nasdaq

Galápagos NV

Logo: Galapagos N.V., Public domain, via Wikimedia Commons4

Belgian pharmaceutical research company

Lakefront Biotherapeutics (formerly known as Galapagos NV and Galapagos Genomics) is a Belgian pharmaceutical research company which was founded in 1999. Its headquarters are located in Mechelen and has additional locations in Leiden, Romainville, Basel, Milan, Madrid, Boston and Zagreb.3 From Wikipedia, CC BY-SA 4.0

Price unavailable

Last updated Oct 18, 2026.

Overview

1.1BRevenue, fiscal 20255
320.9MNet income, fiscal 20255
1999Founded1

Compare with Evotec SE, Ascendis Pharma (Denmark) or Grifols, or pick any stock.

  • TickerLKFT on Nasdaq1
  • Industrypharmaceutical industry1
  • HeadquartersMechelen1
  • Websitewww.glpg.com
  • Legal formPublic limited company (Belgium)1
  • Listed onAmsterdam Stock Exchange (GLPG), Nasdaq (GLPG)1
  • Incorporated inBelgium6
  • Business addressSchalienhoevedreef 20T, 2800 Mechelen6
  • Filer categoryLarge accelerated filer6

See how the biggest companies compare on our leaderboards

Darwinweg 24 Leiden
Photo: Bic, CC BY-SA 4.0, via Wikimedia Commons8

Lakefront Biotherapeutics (formerly known as Galapagos NV and Galapagos Genomics) is a Belgian pharmaceutical research company which was founded in 1999. Its headquarters are located in Mechelen and has additional locations in Leiden, Romainville, Basel, Milan, Madrid, Boston and Zagreb.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from. Figures are in EUR, the currency the company reports in.

Key numbers, fiscal 2025

26.5%Operating margin5
28.9%Net margin5
303.5%Revenue growth, 20255
9.9%Return on equity5
-271.2M EURFree cash flow5

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue3¢29.7M EUR
  • Research and development41¢459.4M EUR
  • Other costs25¢282.6M EUR
  • Interest0¢1.0M EUR
  • Income tax2¢18.6M EUR
  • Profit29¢320.9M EUR

Out of 1.1B EUR in revenue.5

Financial statements

Revenue91011121351.1B EUR in 2025+299% since 2018
0500.0M EUR1.0B EUR1.5B EUR2018: 278.7M EUR278.7M EUR20182019: 834.9M EUR834.9M EUR2019+200%2020: 478.1M EUR478.1M EUR2020−43%2021: 234.4M EUR234.4M EUR2021−51%2022: 241.2M EUR241.2M EUR2022+3%2023: 239.7M EUR239.7M EUR2023−1%2024: 275.6M EUR275.6M EUR2024+15%2025: 1.1B EUR1.1B EUR2025+304%
Operating income9101112135295.0M EUR in 2025
-200.0M EUR0200.0M EUR400.0M EUR2018: -47.1M EUR-47.1M EUR20182019: 368.7M EUR368.7M EUR20192020: -178.6M EUR-178.6M EUR20202021: -171.6M EUR-171.6M EUR2021−4%2022: -131.1M EUR-131.1M EUR2022−24%2023: -88.3M EUR-88.3M EUR2023−33%2024: -188.3M EUR-188.3M EUR2024+113%2025: 295.0M EUR295.0M EUR2025
Net income9101112135320.9M EUR in 2025
-400.0M EUR-200.0M EUR0200.0M EUR400.0M EUR2018: -29.3M EUR-29.3M EUR20182019: 149.8M EUR149.8M EUR20192020: -305.4M EUR-305.4M EUR20202021: -103.2M EUR-103.2M EUR2021−66%2022: -218.0M EUR-218.0M EUR2022+111%2023: 211.7M EUR211.7M EUR20232024: 74.1M EUR74.1M EUR2024−65%2025: 320.9M EUR320.9M EUR2025+333%

Every line of the income statement as filed: the last 3 fiscal years, latest first.5

Period ending2025-12-312024-12-312023-12-31
Supply revenues29.9M EUR34.9M EUR
Collaboration revenues1.1B EUR240.8M EUR239.7M EUR
Total net revenues1.1B EUR275.6M EUR239.7M EUR
Cost of sales-29.7M EUR-34.9M EUR
Research and development expenses-459.4M EUR-335.5M EUR-241.3M EUR
Sales and marketing expenses-6.1M EUR-17.2M EUR-5.7M EUR
General and administrative expenses-147.3M EUR-117.2M EUR-128.3M EUR
Impairment of the cell therapy business-228.1M EUR
Other operating income53.5M EUR40.8M EUR47.3M EUR
Operating loss295.0M EUR-188.3M EUR-88.3M EUR
Fair value adjustments and net exchange differences-39.4M EUR95.8M EUR16.3M EUR
Other financial income48.1M EUR91.1M EUR80.2M EUR
Other financial expenses-2.9M EUR-1.7M EUR-2.6M EUR
Profit / (Loss) (-) before tax300.9M EUR-3.1M EUR5.6M EUR
Income taxes18.6M EUR1.8M EUR-9.6M EUR
Net loss from continuing operations319.5M EUR-1.3M EUR-4.0M EUR
Net profit/(loss) (-) from discontinued operations, net of tax1.4M EUR75.4M EUR215.7M EUR
Net profit / (loss) (-)320.9M EUR74.1M EUR211.7M EUR
Owners of the parent320.9M EUR74.1M EUR211.7M EUR
Basic earnings per share (in EUR per share)4.87 EUR1.12 EUR3.21 EUR
Diluted earnings per share (in EUR per share).4.87 EUR1.12 EUR3.21 EUR
Basic and diluted loss per share from continuing operations (in EUR per share)4.85 EUR-0.02 EUR-0.06 EUR
Basic and Diluted loss per share from continuing operations (in EUR per share).4.85 EUR-0.02 EUR-0.06 EUR
Weighted average number of shares - Basic (in '000 shares)65.9M shares65.9M shares65.9M shares
Weighted average number of shares - Diluted (in '000 shares)65.9M shares65.9M shares65.9M shares

Compare Galápagos NV with another company

The story

Founded by Onno van de Stolpe in 1999.1

Galapagos Genomics NV was founded in 1999 as a joint venture between Crucell and Tibotec. The company later changed its name to Galapagos NV and completed its initial public offering on Euronext Amsterdam and Euronext Brussels in May 2005.

The company uses a technological platform for its research, which is based on adenoviruses to introduce human gene sequences into a wide variety of human cell lines to knock-in or knock-down specific proteins.

In 2019, Gilead Sciences and Galapagos entered into transformative research and development collaboration. Gilead and Galapagos have also agreed to amend certain terms around the development and commercialization of filgotinib.

In June 2022, the business announced it would acquire CellPoint for €125 million, with milestones of up to €100 million and AboundBio for $14million.

Effective April 1, 2022 Paul Stoffels replaced cofounder and CEO of 20 years Onno van de Stolpe.

In April 2026 the company was renamed to Lakefront Biotherapeutics.

From Wikipedia’s article on Lakefront Biotherapeutics, shared under CC BY-SA 4.0.7

Leadership

Who has led Galápagos NV, and when. Pick a name to see everywhere that person has worked.

Board members and other officers (1)

Products and brands

  • filgotinib

Listed on Wikidata.1

Subsidiaries and ownership

Subsidiaries

From Wikidata.1

Former names

  • GALAPAGOS NVNov 14, 2007 to May 6, 20266

Timeline

  1. Jul 29, 2010Went public Listed on NASDAQ1
  2. May 6, 2005Went public Listed on Amsterdam Stock Exchange1
  3. 1999Founded Founded1

Filings

202 filings to the SEC since October 2021: 5 annual reports, 17 large holders, 180 other. The latest 20:

  1. Oct 15, 20266-K EDGAR
  2. Oct 13, 20266-K EDGAR
  3. Oct 9, 20266-K EDGAR
  4. Oct 6, 20266-K EDGAR
  5. Sep 29, 20266-K EDGAR
  6. Sep 23, 20266-K EDGAR
  7. Sep 15, 20266-K EDGAR
  8. Sep 8, 20266-K EDGAR
  9. Sep 8, 20266-K EDGAR
  10. Sep 1, 20266-K EDGAR
  11. Aug 25, 20266-K EDGAR
  12. Aug 25, 20266-K EDGAR
  13. Aug 25, 20266-K EDGAR
  14. Aug 18, 20266-K EDGAR
  15. Aug 12, 20266-K EDGAR
  16. Aug 12, 20266-K EDGAR
  17. Aug 4, 20266-K EDGAR
  18. Jul 28, 20266-K EDGAR
  19. Jul 21, 20266-K EDGAR
  20. Jul 15, 20266-K EDGAR

The 202 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 17 such filings since October 2021, the latest 10:

  1. Jun 23, 2026SCHEDULE 13G
  2. Oct 29, 2025SCHEDULE 13G
  3. Jul 28, 2025SCHEDULE 13D/A
  4. May 19, 2025SCHEDULE 13D/A
  5. Feb 14, 2025SCHEDULE 13D
  6. Jan 10, 2025SCHEDULE 13D/A
  7. Nov 12, 2024SC 13G/A
  8. Oct 8, 2024SC 13D/A
  9. Aug 23, 2024SC 13D
  10. May 2, 2024SC 13D/A

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 77. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Gilead Sciences, Inc.16,707,477$500.2M30.3%No change
Tang Capital Management LLC3,785,991$113.5M5.2%No change
Madison Avenue Partners, LP3,447,807$103.4M4.4%+982,628
Prosight Management, LP2,043,344$61.3M10.6%+493,344
EcoR1 Capital, LLC1,667,119$50.0M2.5%No change
Ameriprise Financial Inc1,272,249$38.1M0.0%−152,425
DME Capital Management, LP482,746$14.5M0.4%No change
Renaissance Technologies LLC407,800$12.2M0.0%+92,400
BlackRock, Inc.338,152$10.1M0.0%+26,046
Point72 Asset Management, L.P.269,814$8.1M0.0%−62,311
D. E. Shaw & Co., Inc.197,844$5.9M0.0%−17,874
Millennium Management LLC181,090$5.4M0.0%+73,178
UBS Group AG168,148$5.0M0.0%−7,141
Susquehanna International Group, Llp151,886$4.6M0.0%+138,499
DAFNA Capital Management LLC130,175$3.9M0.7%No change
Citadel Advisors LLC88,343$2.6M0.0%−36,085
Two Sigma Investments, LP81,749$2.5M0.0%+55,889
Norges Bank76,879$2.3M0.0%New
Alps Advisors Inc65,523$2.0M0.0%+11,862
Goldman Sachs Group Inc56,581$1.7M0.0%+11,210
American Century Companies Inc40,804$1.2M0.0%+2,014
Barometer Capital Management Inc.40,800$1.2M0.3%+2,700
Morgan Stanley37,682$1.1M0.0%+11,063
Schonfeld Strategic Advisors LLC32,597$977.3K0.0%New
Marshall Wace, Llp32,399$971.3K0.0%New

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15